Ann: Nyrada Commences Walter Reed Traumatic Brain Injury Study, page-36

on market potential of a 55 billion dollar target market with already proven function and de risked for both mechanism of action and effectiveness there is nothing priced in except the cash holdings. So yeh 70-100 million market cap is where AGN went to on pre clinical studies before phase 1 so a 4 million dollar EV and coming in with the same price as the directors and CEO is pretty laughable plus also being recognised by the US army with future funding coming from them after Walter reed study which has already been de risked from 2010 pre clinical study laughable